← boothcheck

Is PGNY overvalued?

boothcheck doesn't label PGNY overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-08-10T19:49:04.039Z, anchored at $31.34, PGNY is priced for today's economics sustained for about 5.3 years. The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price. The report narrative was composed 2026-06-28. The more the price assumes beyond what Progyny, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from Progyny, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 28, 2026.

Implied growth
For about5.3 yrs
Held margin (input)
Margin today
Price vs asset value3.18x
Price vs earnings power3.12x
Price vs peer multiples1.20x
Price vs forward growth0.85x
Read the full PGNY report →
Get boothcheck's read on what PGNY's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.